ClinicalTrials.gg
Not yet recruitingNCT07949799FXS6837-I-102Updated Nov 19, 2026

A STUDY OF SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF FXS6837 CAPSULES IN PARTICIPANTS WITH HEPATIC IMPAIRMENT AND NORMAL HEPATIC FUNCTION

A Phase 1 interventional study of FXS6837 capsule in Hepatic Impairment, sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (part of Fosun Pharma) · Phase 1, Interventional, and Other

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a single-center, single-dose, parallel-group, open-label phase I clinical study to evaluate the safety, pharmacokinetics, and pharmacodynamics of FXS6837 between participants with mild and moderate hepatic impairment and participants with normal hepatic function

Read the detailed description

Approximately 24 participants with hepatic impairment and participants with normal hepatic function are planned to be enrolled into this study. Participants will undergo screening examinations from D-28 to D-1. Eligible participants will be admitted to the clinical study site on D-1. During the trial, participants will undergo laboratory tests, 12-lead ECG, vital sign observation, AE collection, and PK, PD, and plasma protein binding (PPB) sample collection.

02

Conditions studied

  • Hepatic Impairment
03

In context

Lead sponsor

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. is the lead sponsor of 37 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged 18-70 years (both inclusive), at screening;
  2. Weight ≥ 50 kg and ≤ 120.0 kg for males, weight ≥ 45 kg and ≤ 120.0 kg for females, and (BMI) 18.0-35.0 kg/m2 (both inclusive), at screening;
  3. Subject is eligible to enter the study if:

    1. matched control subject: physical examination, vital signs, laboratory tests (hematology, serum chemistry, urinalysis, coagulation function, etc.), 12-lead , abdomen ultrasound, and chest X-ray judged by the investigator to be normal or abnormal without clinical significance;
    2. Subject with mild or moderate hepatic impairment:Chronic hepatic impairment caused by primary liver diseases: this condition is defined as patients with a prior diagnosis of hepatic impairment whose liver function is assessed by the investigator to have been stable for ≥ 3 months on the basis of clinical manifestations, with Class A/mild (5-6 points) or Class B/moderate (7-9 points).

Exclusion criteria

Exclusion Criteria:

  1. Patients with serious diseases of cardiovascular, respiratory, digestive, endocrine, renal, hematological, or neurological/psychiatric systems within 1 year prior to screening;
  2. Positive T-SPOT test results during the screening period, considered to indicate active tuberculosis based on the participant's clinical symptoms, chest X-ray, and laboratory tests;
  3. History of meningococcal infection, or history of meningococcal infection in first-degree relatives; Or confirmed history of infection with encapsulated microorganisms within 6 months prior to screening, including but not limited to Streptococcus pneumoniae, Klebsiella pneumoniae, and Haemophilus influenzae;
  4. History of known or suspected immunodeficiency, hereditary or acquired complement deficiency; Or current use of ;
  5. Pregnant or lactating women or those with positive pregnancy test results;
  6. Subjects with hepatic impairment will not be eligible to participate in the study if any of the following exclusion criteria also apply:

    1. Drug-induced liver injury;
    2. History of liver transplantation;
    3. Presence of serious ascites or pleural effusion requiring puncture drainage;
    4. Hepatorenal syndrome;
    5. Diseases affecting biliary excretion, such as biliary cirrhosis, biliary obstruction, and cholestatic liver disease, within 3 months prior to screening;
    6. Serious portal hypertension rendering the patient unsuitable for participating in the study as assessed by the investigator;
    7. History of portosystemic shunt surgery, including transjugular intrahepatic portosystemic shunt;
    8. Current liver failure or complicated with Grade 2-4 hepatic encephalopathy;
    9. Suspected or confirmed liver cancer;
    10. Cirrhosis with complications such as esophageal or gastric variceal bleeding, spontaneous peritonitis, etc., that the investigator considers unsuitable for participation in the study, within 3 months prior to screening;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Mild hepatic impairment

    Arm 1:mild hepatic impairment, FXS6837 125mg orally once.

    Drug: FXS6837 capsule

  • Experimental
    Moderate hepatic impairment

    Arm 2: moderate hepatic impairment, FXS6837 125mg orally once.

    Drug: FXS6837 capsule

  • Experimental
    Normal hepatic function

    Arm 3: normal hepatic function FXS6837 125mg orally once.

    Drug: FXS6837 capsule

Interventions

  • DrugFXS6837 capsule

    Mild hepatic impairment, FXS6837 125mg orally once.

06

What researchers measure

Primary outcomes

  1. Primary Pharmacokinetics(PK) parameter of FXS6837 in plasma:Cmax

    Maximum observed concentration (Cmax)

    Time frame: Up to Day 14

  2. Primary PK parameter of FXS6837 in plasma: AUC0-t

    Area under the plasma concentration-time curve from time 0 to time t (AUC0-t)

    Time frame: Up to Day 14

  3. Primary PK parameter of FXS6837 in plasma: AUC0-∞

    area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞)

    Time frame: Up to Day 14

Secondary outcomes

  1. Secondary PK parameter of FXS6837 in plasma: Tmax

    Time to reach maximum concentration(Tmax)

    Time frame: Up to Day 14

  2. Secondary PK parameter of FXS6837 in plasma: t1/2

    Half-life (t1/2)

    Time frame: Up to Day 14

  3. Secondary PK parameter of FXS6837 in plasma: CL/F

    Apparent total plasma clearance (CL/F)

    Time frame: Up to Day 14

  4. Secondary PK parameter of FXS6837 in plasma: Vz/F

    Apparent terminal volume of distribution (Vz/F)

    Time frame: Up to Day 14

  5. PK parameter of unbound FXS6837 in plasma: Cmax,u

    Maximum unbound concentration (Cmax, u)

    Time frame: Up to Day 14

  6. PK parameter of unbound FXS6837 in plasma: AUC0-t, u

    Area under the unbound plasma concentration-time curve from time 0 to time t (AUC0-t, u)

    Time frame: Up to Day 14

  7. PK parameter of unbound FXS6837 in plasma: AUC0-∞, u

    Area under the unbound plasma concentration-time curve from time 0 to infinity (AUC0-∞, u)

    Time frame: Up to Day 14

  8. Incidence and severity of AE and SAE

    Incidence and severity of adverse events (AEs)/serious adverse events (SAEs), including abnormalities in clinical symptoms and vital signs, physical examination, 12-lead electrocardiogram (ECG), and laboratory tests

    Time frame: Up to Day 14

  9. Pharmacodynamics indicator of FXS6837. Change from baseline in peripheral blood complement Alternative Pathway activity

    Complement alternative pathway (AP) activity in peripheral blood.Complement alternative pathway (AP) activity will be measured in peripheral blood. Absolute change and percentage change from baseline to Day 5 will be assessed.

    Time frame: Up to Day 5

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Apr 2027, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 19, 2026
StartEst.
Dec 17, 2026
Primary completionEst.
Apr 29, 2027
CompletionEst.
Jun 1, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949799
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Dec 17, 2026 (estimated)
Primary completion
Apr 29, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion